The earnings call highlighted significant revenue growth and strong demand projections for the future. However, challenges such as the tragic patient safety incident, administrative delays, and site capacity imbalances have led to a downward revision of revenue guidance. Despite these challenges, the company remains optimistic about long-term demand and continues to work on addressing the issues.

Company Guidance -

Q3 2025

During the call, Sarepta Therapeutics updated its guidance for the year, projecting net product revenue between $2.3 billion and $2.6 billion across its four approved therapies. This adjustment reflects several factors, including a significant safety event involving their gene therapy product ELEVIDYS, which contributed to delays in patient treatment. The company reported first-quarter total net product revenue of $612 million, marking a 70% increase compared to the previous year, with ELEVIDYS achieving sales of $375 million, a 180% increase. While the PMO franchise grew by 5% to $237 million, the company anticipates a 20% revenue decrease in Q2 compared to Q1 due to ongoing impacts from the safety event and administrative challenges. Sarepta emphasized its commitment to improving patient access and education while addressing site capacity issues to support revenue growth for the remainder of 2025.

Strong Revenue Growth

Sarepta achieved $612 million in total net product revenue for the first quarter of 2025, representing 70% growth over the same quarter last year.

ELEVIDYS Sales Increase

ELEVIDYS achieved sales of $375 million in the quarter, representing a 180% increase over the same quarter last year.

Successful PMO Franchise Growth

The PMO franchise grew 5%, achieving $237 million for the quarter.

Positive Long-Term Demand Outlook

Despite short-term challenges, Sarepta projects a pickup in demand beginning in the summer and extending through the remainder of the year, maintaining confidence in the long-term demand outlook for ELEVIDYS.

Sarepta Therapeutics (SRPT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

SRPT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 29, 2025	2025 (Q3)	-0.51 / -	0.34	―	―	―
Aug 06, 2025	2025 (Q2)	0.83 / 1.89	0.07	2600.00% (+1.82)	―	―
May 06, 2025	2025 (Q1)	-3.21 / -4.60	0.37	-1343.24% (-4.97)
Feb 26, 2025	2024 (Q4)	1.88 / 1.50	0.47	219.15% (+1.03)
Nov 06, 2024	2024 (Q3)	-0.07 / 0.34	-0.46	173.91% (+0.80)	―
Aug 07, 2024	2024 (Q2)	-0.13 / 0.07	-0.27	125.93% (+0.34)	―
May 01, 2024	2024 (Q1)	0.01 / 0.37	-5.86	106.31% (+6.23)	―
Feb 28, 2024	2023 (Q4)	0.07 / 0.47	-1.24	137.90% (+1.71)	―
Nov 01, 2023	2023 (Q3)	-1.22 / -0.46	-2.94	84.35% (+2.48)	―
Aug 02, 2023	2023 (Q2)	-1.78 / -0.27	-2.65	89.81% (+2.38)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

SRPT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$16.26	$17.96	+10.46%
May 06, 2025	$46.75	$36.72	-21.45%
Feb 26, 2025	$106.86	$103.06	-3.56%
Nov 06, 2024	$127.97	$120.42	-5.90%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.